Noticias y vídeos - SOSEI CO LTD. SOLTF - Inglés - Página 4

Tokyo, Japan and Cambridge , UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, is pleased to announce it has received approval from the Tokyo Stock Exchange, Inc. (“TSE”) to change the market on which the Company's shares are listed from the Growth Market segment to the Prime Market segment, effective March 15, 2023. We are deeply grateful to our...

Tokyo, Japan and Cambridge , UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2022. The full report can be found here . Chris Cargill, President & CEO of Sosei Heptares, commented: “2022 was a very important and successful year for...

TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, will announce its earnings results and present operational highlights for the 12 months ended 31 December 2022 on Tuesday, 14 February 2023. The Company will host a webinar presentation in-person and virtually for institutional investors, securities analysts...

TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero Bio Phase 1 study in healthy volunteers expected to begin in Q1 2023 with support from a US$5.3M grant from the US National Institute on Drug Abuse (NIDA) Tempero Bio was created by Aditum Bio in collaboration with Sosei Heptares in 2020 to advance the clinical development of mGluR5 NAM candidates to develop...

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trials Dosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10 million to Sosei Heptares TOKYO and CAMBRIDGE, United Kingdom, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by Pfizer that...

TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41 st Annual J.P. Morgan Healthcare Conference. The presentation will take place in-person at the JW Marriott Hotel, San Francisco Union Square, and via webcast at 1:30pm Pacific Standard Time on Wednesday, 11 January 2023. An audio link to the Company’s webcast presentation can be accessed here ....

New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertise Sosei Heptares eligible to receive US$37 million upfront in cash and further development and commercial milestone payments totalling up to US$694 million plus tiered royalties TOKYO and CAMBRIDGE, United Kingdom, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces it has...

TOKYO and CAMBRIDGE, United Kingdom, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces that it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune diseases. The achievement triggers a payment of US$10 million to Sosei...

Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based drug design TOKYO and CAMBRIDGE, United Kingdom, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces it...

TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and first nine months ended 30 September 2022. The full report can be found here . Chris Cargill, President and CEO of Sosei Heptares, commented: “We have made exciting progress during the third quarter of 2022, building on the strategic and operational initiatives we...

TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK R&D, will participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference on Tuesday, 15 November at 11:30 a.m. GMT / 6:30 a.m. ET / 8:30 p.m. JST. The live webcast of the ‘Fireside Chat’ will be available here . The replay will also be available at the same link for 90 days...

NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, notes its partner Neurocrine Biosciences Inc. (“Neurocrine”) announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study...

TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The meeting will be held in person in Tokyo for institutional investors, securities analysts and the press and will also be available via a live webcast. Please click here to register for the event. Date: Thursday, 13 October 2022 Time: 3:30 pm – 5:30 pm JST (7:30 am – 9:30 am BST) Presenters: Chris...

TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and development, is pleased to announce it has won Licensing Deal of the Year and Executive of the Year at the first Informa Pharma Intelligence Awards Japan held yesterday in Tokyo. The Informa Pharma Intelligence Awards Japan, the Japanese rendition of the...

TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2022. The full report can be found by clicking here . Chris Cargill, President and CEO of Sosei Heptares, commented: “The first half of 2022 has been an exciting period for Sosei Heptares. Our new leadership team has settled in...

Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment of US$30 million to Sosei Heptares from Neurocrine NBI-1117568 is the most advanced candidate under the multi-program muscarinic receptor agonist collaboration between Sosei Heptares and Neurocrine TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the...

New strategic collaboration leverages Sosei Heptares’ StaR ® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseases Sosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties TOKYO, Japan and CAMBRIDGE, United Kingdom,...

TOKYO, Japan and LONDON and CAMBRIDGE, United Kingdom, July 22, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR 1 -focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial. Under...

TOKYO, Japan and CAMBRIDGE, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2022 on Wednesday, 10 August 2022. The Company will host a webinar presentation with Chris Cargill, President and CEO, Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, and Hironoshin Nomura, CFO, at 5 pm JST (9 am BST) on Wednesday, 10 August...

TOKYO, Japan and CAMBRIDGE, United Kingdom, May 26, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has expanded its UK R&D operations into a second site within Granta Park, Cambridge, to The Cori Building, previously occupied by Cancer Research UK. The requirement for additional R&D space is being driven by the Company’s strategy to...